IP Library Granted Patent US 8,614,243
Granted Patent B2
US 8,614,243 · App. 12/796,587 · Granted Dec 24, 2013

Small-molecule modulators of Trp-p8 activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,614,243
App. No.
12/796,587
Granted
Dec 24, 2013
Kind
B2
Abstract

Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.

Claims (17)

1. A compound of Formula I-B:

wherein

R 1 is selected from the group consisting of H, alkyl, heteroalkyl, aryl, and arylalkyl;

R 2a is selected from the group consisting of aryl, alkyl, heteroalkyl, and arylalkyl;

R 3 is selected from the group consisting of alkyl, heteroalkyl, and arylalkyl;

R 4 is selected from the group consisting of H, alkyl, heteroalkyl, and arylalkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 1 is H.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 3 is alkyl, heteroalkyl or arylalkyl, each of which has 1, 2, 3, 4, 5, or 6 carbons.

4. The compound of claim 3 or a pharmaceutically acceptable salt thereof wherein R 3 is selected from methylene, ethylene, propylene, and butylene.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 4 is selected from H and methyl.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 2a is a group selected from phenyl, furan, methylpyrrole, methylbenzoate, aminophenyl, hydroxyphenyl, cyanophenyl, and methoxyphenyl.

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein the moiety:

is selected from the group consisting of 2-(2-amino-ethyl)-5-furan-2-yl-2H-pyrazol-3-yl, 2-(2-amino-propyl)-5-phenyl-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-phenyl-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazol-3-yl, 2-(2-amino-propyl)-5-phenyl-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-(4-amino-phenyl)-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-(4-hydroxy-phenyl)-2H-pyrazol-3-yl, 2-(2-methylamino-ethyl)-5-phenyl-2H-pyrazol-3-yl, 2-(2-amino-propyl)-5-phenyl-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-(3-cyano-phenyl)-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-(3-methoxy-phenyl)-2H-pyrazol-3-yl, 4-{1-(2-Amino-ethyl)-1H-pyrazol-3-yl}-benzoic acid methyl ester, 2-(2-amino-ethyl)-5-(3-amino-phenyl)-2H-pyrazol-3-yl, and 2-(2-amino-ethyl)-5-(3-hydroxy-phenyl)-2H-pyrazol-3-yl.

8. The compound of claim 7 wherein said compound is 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-ethyl)-5-furan-2-yl-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-propyl)-5-phenyl-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-ethyl)-5-phenyl-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-ethyl)-5-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-propyl)-5-phenyl-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-ethyl)-5-(4-amino-phenyl)-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-ethyl)-5-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-methylamino-ethyl)-5-phenyl-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-propyl)-5-phenyl-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[, 2-(2-amino-ethyl)-5-(3-cyano-phenyl)-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-ethyl)-5-(3-methoxy-phenyl)-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[4-{1-(2-amino-ethyl)-1H-pyrazol-3-yl}-benzoic acid methyl ester]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-ethyl)-5-(3-amino-phenyl)-2H-pyrazol-3-yl]-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid-[2-(2-amino-ethyl)-5-(3-hydroxy-phenyl)-2H-pyrazol-3-yl]-amide or a pharmaceutically acceptable salt thereof.

9. The compound of claim 8 in isolated or purified form.

10. A pharmaceutical composition comprising a compound of claim 1 , and combinations thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042389 FRAME: 505. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Feb 14, 2018
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 046088/0882 →
RELEASE OF SECURITY INTEREST Recorded Jul 5, 2017
From: BARCLAYS BANK PLC
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 043089/0288 →
CHANGE OF NAME Recorded May 3, 2017
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 042389/0505 →